Objectivity Squared LLC Takes $2.45 Million Position in Danaher Corporation $DHR

Objectivity Squared LLC purchased a new stake in Danaher Corporation (NYSE:DHR) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,397 shares of the conglomerate’s stock, valued at approximately $2,446,000. Danaher makes up approximately 1.4% of Objectivity Squared LLC’s portfolio, making the stock its 10th largest holding.

A number of other hedge funds have also bought and sold shares of DHR. Bell Investment Advisors Inc acquired a new stake in Danaher in the 2nd quarter worth about $47,000. State of Wyoming acquired a new position in shares of Danaher during the 2nd quarter worth approximately $74,000. Elevated Capital Advisors LLC bought a new position in shares of Danaher during the fourth quarter worth approximately $26,000. Hilton Head Capital Partners LLC bought a new position in shares of Danaher during the fourth quarter worth approximately $27,000. Finally, Clal Insurance Enterprises Holdings Ltd raised its position in shares of Danaher by 71.6% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock valued at $29,000 after buying an additional 53 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Stock Performance

NYSE:DHR opened at $202.44 on Tuesday. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The stock’s 50-day simple moving average is $193.52 and its 200 day simple moving average is $192.67. The firm has a market capitalization of $142.31 billion, a PE ratio of 35.96, a price-to-earnings-growth ratio of 2.52 and a beta of 0.78.

Danaher (NYSE:DHR) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The firm had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter in the previous year, the firm earned $0.77 earnings per share. The business’s quarterly revenue was up 5.5% on a year-over-year basis. On average, analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. HSBC cut their price target on Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. JPMorgan Chase & Co. dropped their price objective on Danaher from $275.00 to $245.00 and set an “overweight” rating for the company in a report on Wednesday, April 22nd. Argus cut their target price on Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a research report on Friday, April 24th. Piper Sandler assumed coverage on Danaher in a report on Thursday, June 11th. They set a “neutral” rating and a $200.00 target price on the stock. Finally, Wolfe Research cut Danaher from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $228.91.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.